{"prompt": "['Product: MK-3475', '32', 'Protocol/Amendment No.: 604-09', 'spectrometry. This approach could identify novel protein biomarkers to aid in patient', 'selection for pembrolizumab therapy.', 'Other blood derived biomarkers: In addition to expression on the tumor tissue, PD-L1 and', 'other tumor-derived proteins can be shed from tumor and released into the blood. Assays', 'such as enzyme-linked immunoassays measure these proteins in serum. The correlation of', 'such expression with a response to pembrolizumab therapy may lead to identification of new', 'approaches for using predictive biomarkers in blood, representing a major advance from', \"today's reliance on assessing tumor biomarkers. This research would serve to develop such\", 'assays for future clinical use.', '4.2.3.7 Future Biomedical Research', 'The Sponsor will conduct Future Biomedical Research on specimens consented for future', 'biomedical research during this clinical trial. This research may include genetic analyses', '(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or', 'the measurement of other analytes, depending on which specimens are consented for future', 'biomedical research.', 'Such research is for biomarker testing to address emergent questions not described elsewhere', 'in the protocol (as part of the main trial) and will only be conducted on specimens from', 'appropriately consented subjects. The objective of collecting/retaining specimens for Future', 'Biomedical Research is to explore and identify biomarkers that inform the scientific', 'understanding of diseases and/or their therapeutic treatments. The overarching goal is to use', 'such information to develop safer, more effective drugs/vaccines, and/or to ensure that', 'subjects receive the correct dose of the correct drug/vaccine at the correct time. The details', 'of this Future Biomedical Research sub-trial are presented in Section 12.2 - Collection and', 'Management of Specimens for Future Biomedical Research.', '4.3 Benefit/Risk', 'It cannot be guaranteed that subjects in clinical trials will directly benefit from treatment', 'during participation, as clinical trials are designed to provide information about the safety', 'and effectiveness of an investigational medicine.', 'As described in Section 4.2.1, KEYNOTE-028 demonstrated that pembrolizumab', 'monotherapy has meaningful anti-tumor activity in heavily pre-treated subjects with', 'PD-L1-positive SCLC. Pembrolizumab in combination with chemotherapy has significant', 'clinical activity as 1L therapy in subjects with advanced NSCLC, regardless of PD-L1', 'expression, as shown in KEYNOTE-021 Cohort G (Section 4.2.1). Considering the high', 'unmet medical need for new and tolerable treatment options in subjects with newly', 'diagnosed ES-SCLC, the anti-tumor activity and the favorable safety profile of', 'pembrolizumab in combination with chemotherapy regimens for other solid tumors, a', 'combination of PD-1 blockade plus chemotherapy is a promising therapeutic strategy and the', 'benefit-risk assessment for subjects included in this trial is considered to be favorable.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '33', 'Protocol/Amendment No.: 604-09', 'Additional details regarding specific benefits and risks for subjects participating in this', 'clinical trial may be found in the accompanying IB and informed consent documents.', '5.0 METHODOLOGY', '5.1', 'Entry Criteria', '5.1.1 Diagnosis/Condition for Entry into the Trial', 'Male and female subjects with ES-SCLC will be enrolled in this trial.', '5.1.2 Subject Inclusion Criteria', 'In order to be eligible for participation in this trial, the subject must:', '1. Have a documented new diagnosis of SCLC by histology or cytology from brushing,', 'washing, or needle aspiration of a defined lesion. Subjects who do not have histology', 'samples (defined as core or excisional biopsy, or resections) will need to undergo a', 'new biopsy to provide a tissue sample.', '2. Have extensive stage disease defined as Stage IV (T any, N any, M 1a/b) by the', 'American Joint Committee on Cancer, Seventh Edition.', '3. Have at least 1 lesion that meets the criteria for being measurable, as defined by', 'RECIST 1.1, and is appropriate for selection as a target lesion, as determined by local', 'site investigator/radiology review. Lesions that appear measurable, but have', 'undergone palliative irradiation, cannot be target lesions.', '4. Have provided archival tumor tissue sample or newly obtained core or excisional', 'biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin-embedded', 'tissue blocks are preferred to slides.', '5. Have ECOG Performance Status of 0 or 1. See Section 12.3 for definitions.', '6. Have a life expectancy of at least 3 months.', '7. Have adequate organ function as indicated by the following laboratory values', '(Table 1).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}